Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study

Basit Öğe Kaydı
dc.contributor.authorSerarslan, Gamze
dc.contributor.authorUzun, Mehmet
dc.contributor.authorDogramaci, Asena Cigdem
dc.contributor.authorCelik, Ebru
dc.date.accessioned2024-09-18T19:54:21Z
dc.date.available2024-09-18T19:54:21Z
dc.date.issued2019
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAntihistamines are the first-line treatment option for chronic urticaria. In recent years, omalizumab, an anti-immunoglobulin-E humanized monoclonal antibody, has been used in patients with recalcitrant disease. The present study aimed to retrospectively evaluate the efficacy and safety of omalizumab and determine whether there was a difference between complete and partial responses to omalizumab with respect to age, gender, disease duration and coexistence of angioedema. From May 2014 to December 2016, a total of 40 refractory chronic urticaria patients were treated with omalizumab. Complete response was observed in 19 (47.5%) patients, and partial response was observed in 18 (45%) patients. There were no statistically significant differences between the rates of complete and partial responses in patients with respect to gender, age, and disease duration. However, complete response was more frequent (60%) in patients without angioedema. Remission was observed in 40.5% (n = 15) of patients, and the follow-up time was 5.5 +/- 2.4 months. There was a statistically significant association between remission and coexistence of angioedema (p < .05). Eighty-seven percent (13/15) of the remission patients did not have angioedema. Thus, omalizumab can be used effectively and safely in refractory chronic urticaria patients. However, the coexistence of angioedema may be an unfavorable factor for complete response and remission.en_US
dc.identifier.doi10.1111/dth.12752
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.issue1en_US
dc.identifier.pmid30238582en_US
dc.identifier.scopus2-s2.0-85055936463en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1111/dth.12752
dc.identifier.urihttps://hdl.handle.net/20.500.12483/7682
dc.identifier.volume32en_US
dc.identifier.wosWOS:000457760600004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofDermatologic Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectangioedemaen_US
dc.subjectchronicen_US
dc.subjectomalizumaben_US
dc.subjecturticariaen_US
dc.titleAngioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
7682.pdf
Boyut:
420.54 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu